--- title: "The Hong Kong Misfit Toys: From Solid Cash Cows to Epic Frauds" type: "News" locale: "en" url: "https://longbridge.com/en/news/294333276.md" description: "Digging through unclassified Hong Kong equities is like a bizarre garage sale. We see solid fundamentals from JNBY and Yeahka, contrasted by New Horizon Health's epic fake-stool delisting scandal." datetime: "2026-07-30T09:13:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294333276.md) - [en](https://longbridge.com/en/news/294333276.md) - [zh-HK](https://longbridge.com/zh-HK/news/294333276.md) generator: "portal-rs" --- # The Hong Kong Misfit Toys: From Solid Cash Cows to Epic Frauds I have seen this “Island of Misfit Toys” playbook in Hong Kong equities too many times to count. You gather a bunch of unclassified leftovers, wait for a macro breeze, and pretend they all have a coherent narrative. This is stupid and here’s why: throwing a fashion retailer, a construction heavyweight, and a cement maker into the same bucket is a lazy analyst’s dream and a fundamental nightmare. But if you want to understand the extreme duality of the 2026 market, look no further. Let’s start with the companies that are actually making a buck. 江南布衣 (3306.HK) is proving that knowing your audience pays off. They delivered a solid 7% revenue bump in the first half of fiscal 2026, fueled by an incredibly sticky base of nearly 600,000 active members. 移卡 (3200.HK) is quietly expanding its footprint, securing US state licenses back in 2025 and pushing aggressively into Japan. Meanwhile, 中国建筑国际 (3311.HK) might have seen a revenue dip in Q1 2026, but its rock-solid positive cash flow and healthy dividend payouts make it a reliable anchor in this chaotic sea. Then we pivot to biotech, where things get utterly surreal. On the functional side, 绿叶制药 (2186.HK) is moving the needle with successful Phase II trials for its new drug in 2026, driving its shares visibly higher recently. 康圣环球 (9890.HK) pivoted hard into solid tumor screening in 2025 just to survive a brutal industry shakeout. But then there is 诺辉健康 (3189.HK). Oh, New Horizon Health. This was supposed to be the crown jewel of early cancer screening. Instead, they got unceremoniously delisted in late 2025 for a fraud so spectacular it belongs in a Scorsese film. They literally bought feces from public toilets to forge testing samples and inflate revenue. Nearly 4 billion RMB lost over three years, masked by literal crap. Why aren't auditors moving faster on this garbage? Good luck to the early backers who bought into that fairy tale. Finally, we have the ghost ships. 保利文化 (6060.HK) somehow pushed through an IPO in 2026 despite a bleeding balance sheet in recent years. And names like 电视广播 (0511.HK), 亚洲水泥 (中国) (0746.HK), and 利福国际 (0901.HK) are just floating in the void with zero market pulse right now. Wake up, or the market will forget you exist entirely. *This article does not constitute investment advice.* ### Related Stocks - [09890.HK](https://longbridge.com/en/quote/09890.HK.md) - [03311.HK](https://longbridge.com/en/quote/03311.HK.md) - [03306.HK](https://longbridge.com/en/quote/03306.HK.md) - [06060.HK](https://longbridge.com/en/quote/06060.HK.md) - [03200.HK](https://longbridge.com/en/quote/03200.HK.md) - [02186.HK](https://longbridge.com/en/quote/02186.HK.md) ## Related News & Research - [GuoSen Sticks to Their Buy Rating for JNBY Design (JNBYF)](https://longbridge.com/en/news/298821531.md) - [Guotai Haitong Reaffirms Their Buy Rating on JNBY Design (JNBYF)](https://longbridge.com/en/news/298869544.md) - [Popularity of Pet Insurance in China Increases as Penetration Rate Reaches 4%](https://longbridge.com/en/news/299008143.md) - [JNBY Design Sets AGM to Approve Dividends, Share Awards and New Issuance Mandate](https://longbridge.com/en/news/298468620.md) - [JNBY FY Net Profit Rises 11.7% YoY to RMB997 Million; Final DPS Plus Special Div Totals HKD1.81](https://longbridge.com/en/news/298523358.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**